Physician profile
Jodumutt Bhat
NPI 1356390603
$4,197.19
in general payments reported to CMS, 2019-2025
12 companies · $78.17 in 2025
The $78.17 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $59.57 · 2022: $87.12 · 2023: $1,272 · 2024: $2,401 · 2025: $78.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,005 · Consulting Fee: $1,180 · Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,005.00 |
| Consulting Fee | $1,180.00 |
| Food and Beverage | $566.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $2,344.64 | 2024 | |
| Akebia Therapeutics INC | $1,319.96 | 2020-2025 | Auryxia, Vafseo |
| Fresenius USA Marketing, INC. | $334.03 | 2019-2020 | |
| Gastroklenz, INC. Dba Cloudcath | $119.09 | 2022-2024 | |
| Ardelyx, INC. | $31.33 | 2025 | Ibsrela |
| Vifor Pharma, INC. | $25.43 | 2023 | Veltassa |
| Renalytix Ai, INC. | $22.71 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodumutt Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.